

Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-Nov-2020
 Document Type: USP Monographs
 DocId: GUID-2286DE7A-CAA7-4359-80B1-4E2CDF28066D_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M25878_02_01
 DOI Ref: b59j3

© 2025 USPC
 Do not distribute

Diflunisal Tablets

DEFINITION

Diflunisal Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of diflunisal ($C_{13}H_8F_2O_3$).

IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

Delete the following:

▲ • B. THIN-LAYER CHROMATOGRAPHY

Standard solution: 10 mg/mL of [USP Diflunisal RS](#) in [methanol](#) and [water](#) (80:20)

Sample solution: Nominally 10 mg/mL of diflunisal prepared as follows. Transfer a quantity of finely ground Tablets, equivalent to about 100 mg of diflunisal, to a 10-mL volumetric flask. Add 2 mL of [water](#), and sonicate for 5 min. Dilute with [methanol](#) to volume, sonicate for an additional 5 min, and pass through a suitable filter.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Adsorbent: 0.25-mm layer of chromatographic silica gel mixture

Application volume: 10 µL

Developing solvent system: *n*-Hexane, [glacial acetic acid](#), and chloroform (17:3:2)

Analysis

Samples: *Standard solution* and *Sample solution*

Develop the chromatogram until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the chamber, air-dry, and examine under long-wavelength UV light.

Acceptance criteria: The R_F value of the principal spot of the *Sample solution* corresponds to that of the *Standard solution*. ▲ (USP 1-May-2020)

Add the following:

- ▲ • **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay. ▲ (USP 1-May-2020)

ASSAY

Change to read:

• PROCEDURE

▲ **Mobile phase:** [Methanol](#), [acetonitrile](#), [glacial acetic acid](#), and [water](#) (40:17:6:45)

Diluent: [Acetonitrile](#) and [water](#) (60:40)

Standard solution: 0.1 mg/mL of [USP Diflunisal RS](#) in *Diluent*. Sonicate to dissolve as needed.

Sample stock solution: Nominally 1 mg/mL of diflunisal prepared as follows. Finely powder Tablets (NLT 20). Transfer a quantity of the powder, equivalent to about 100 mg of diflunisal, to a 100-mL volumetric flask. Add 5 mL of [water](#) and sonicate for 5 min. Add 60 mL of [acetonitrile](#), and sonicate with occasional shaking for 10 min. Dilute with [water](#) to volume. Pass through a suitable filter of 0.45-µm pore size. Discard the first few milliliters of the filtrate.

Sample solution: Nominally 0.1 mg/mL of diflunisal in *Diluent* from *Sample stock solution*

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 254 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.

Column: 4.6-mm × 15-cm; 5-µm packing [L1](#)

Column temperature: 40°

Flow rate: 1.5 mL/min

Injection volume: 10 µL

Run time: NLT 2 times the retention time of diflunisal ▲ (USP 1-May-2020)

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of diflunisal ($C_{13}H_8F_2O_3$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of diflunisal from the *Sample solution*

r_S = peak response of diflunisal from the *Standard solution*

C_S = concentration of [USP Diflunisal RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of diflunisal in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

Change to read:

• [DISSOLUTION \(711\)](#)

Citric acid solution: Dissolve 7 g of [anhydrous citric acid](#) in 100 mL of [water](#).

0.1 M tris buffer: Dissolve 121 g of [tris\(hydroxymethyl\)aminomethane](#) (THAM) in 9 L of [water](#). Adjust with *Citric acid solution* to a pH of 7.45, at 25°. Dilute with [water](#) to 10.0 L, equilibrate to 37°, and adjust to a pH of 7.20, if necessary.

Medium: 0.1 M tris buffer, 900 mL

Apparatus 2: 50 rpm

Time: 30 min

Standard solution: A known concentration of [USP Diflunisal RS](#) in *Medium*

Sample solution: Pass a portion of the solution under test through a suitable filter. Dilute with *Medium*, if necessary.

Instrumental conditions

▲ (See [Ultraviolet-Visible Spectroscopy \(857\)](#).) ▲ (USP 1-May-2020)

Mode: UV

Analytical wavelength: 306 nm

▲ Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of diflunisal ($C_{13}H_8F_2O_3$) dissolved:

$$\text{Result} = (A_U/A_S) \times C_S \times D \times V \times (1/L) \times 100$$

A_U = absorbance of the *Sample solution*

A_S = absorbance of the *Standard solution*

C_S = concentration of [USP Diflunisal RS](#) in the *Standard solution* (mg/mL)

D = dilution factor of the *Sample solution*

V = volume of *Medium*, 900 mL

L = label claim (mg/Tablet)

▲ (USP 1-May-2020)

Tolerances: NLT 80% (Q) of the labeled amount of diflunisal ($C_{13}H_8F_2O_3$) is dissolved.

Change to read:

• [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

▲ (USP 1-May-2020)

IMPURITIES

Add the following:

▲• ORGANIC IMPURITIES

Mobile phase: [Methanol](#), [acetonitrile](#), [glacial acetic acid](#), and [water](#) (36:15:6:50)

Diluent: [Acetonitrile](#) and [water](#) (60:40)

Sensitivity solution: 1 µg/mL of [USP Diflunisal RS](#) in *Diluent*. Sonicate to dissolve as needed.

Standard solution: 2 µg/mL of [USP Diflunisal RS](#) in *Diluent*. Sonicate to dissolve as needed.

Sample solution: Prepare as directed in the *Sample stock solution* in the Assay.